Full Text:
<694>
CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 0000-00-00
Cited: 0
Clicked: 746
Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer
| |||||||||||||
Jiajie FANG, Ahmad ALHASKAWI, Yanzhao DONG, Cheng CHENG, Zhijie XU, Junjie TIAN, Sahar Ahmed ABDALBARY, Hui LU. Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer[J]. Journal of Zhejiang University Science B, 1998, -1(-1): .
@article{title="Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer",
author="Jiajie FANG, Ahmad ALHASKAWI, Yanzhao DONG, Cheng CHENG, Zhijie XU, Junjie TIAN, Sahar Ahmed ABDALBARY, Hui LU",
journal="Journal of Zhejiang University Science B",
volume="-1",
number="-1",
pages="",
year="1998",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2300614"
}
%0 Journal Article
%T Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer
%A Jiajie FANG
%A Ahmad ALHASKAWI
%A Yanzhao DONG
%A Cheng CHENG
%A Zhijie XU
%A Junjie TIAN
%A Sahar Ahmed ABDALBARY
%A Hui LU
%J Journal of Zhejiang University SCIENCE B
%V -1
%N -1
%P
%@ 1673-1581
%D 1998
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2300614
TY - JOUR
T1 - Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer
A1 - Jiajie FANG
A1 - Ahmad ALHASKAWI
A1 - Yanzhao DONG
A1 - Cheng CHENG
A1 - Zhijie XU
A1 - Junjie TIAN
A1 - Sahar Ahmed ABDALBARY
A1 - Hui LU
J0 - Journal of Zhejiang University Science B
VL - -1
IS - -1
SP -
EP -
%@ 1673-1581
Y1 - 1998
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2300614
Abstract: prostate cancer is the second most common cancer in men, accounting for 14.1% of new cancer cases in 2020. The aggressiveness of prostate cancer is highly variable, depending on its grade and stage at the time of diagnosis. Despite recent advances in prostate cancer treatment, some patients still experience recurrence or even progression after undergoing radical treatment. Accurate initial staging and monitoring for recurrence determines patient management, which in turn affects patient prognosis and survival. Classical imaging has limitations in the diagnosis and treatment of prostate cancer, but the use of novel molecular probes has improved the detection rate, specificity, and accuracy of prostate cancer detection. Molecular probe-based imaging modalities allow the visualization and quantitative measurement of biological processes at the molecular and cellular levels in living systems. An increased understanding of tumor biology of prostate cancer and the discovery of new tumor biomarkers have allowed the exploration of additional molecular probe targets. The development of novel ligands and advances in nano-based delivery technologies have accelerated the research and development of molecular probes. Here, we summarize the use of molecular probes in PET, SPECT, MRI, optical imaging, and ultrasound imaging, and provide a brief overview of important target molecules in prostate cancer.
Open peer comments: Debate/Discuss/Question/Opinion
<1>